Pharmacotherapy of patients with schizophrenia and substance abuse

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 3, 2009, Pages 353-367

  Wobrock, Thomas ^a   Soyka, Michael ^b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Department of Psychiatry and Psychotherapy   (Switzerland)

Author keywords

Antipsychotics; Pharmacotherapy; Schizophrenia; Substance abuse

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; DIBENZEPIN; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; DISULFIRAM; FLUPHENAZINE DECANOATE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NALMEFENE; NALOXONE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; THIOXANTHENE DERIVATIVE; VALPROIC ACID; DRUGS USED IN THE TREATMENT OF ADDICTION; TRANQUILIZER;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; CANNABIS ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; DEPRESSION; DISEASE EXACERBATION; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; HUMAN; MENTAL DISEASE; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT INDICATION; TREATMENT OUTCOME; ADDICTION; DRUG COMBINATION; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL ASPECT; PSYCHOLOGY;

ALCOHOL DETERRENTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DUAL (PSYCHIATRY); DISULFIRAM; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

EID: 65649137280     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802694655     Document Type: Review

References (106)

1. Wobrock T, Pajonk FG, D'Amelio R, Falkai P. Schizophrenia and addiction. PsychoNeuro 2005;31(9):433-440
2. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001;48(1):69-82 • Review of the prevalence of comorbid substance abuse in schizophrenia.
3. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 1990;16(1):31-56 (Pubitemid 20110374)
4. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-8 • Population-based study presenting data on the prevalence of comorbid substance abuse in different psychiatric conditions.
5. Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 1990;147(5):602-607 (Pubitemid 20153430)
6. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152(6):856-861
7. Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997;23(2):195-201 (Pubitemid 27224872)
8. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51(4):273-279 (Pubitemid 24127299)
9. Rasanen P, Tiihonen J, Isohanni M, et al. Schizophrenia, alcohol abuse, and violent behavior: a 26-year followup study of an unselected birth cohort. Schizophr Bull 1998;24(3):437-441 (Pubitemid 28378228)
10. Seibyl JP, Satel SL, Anthony D, et al. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis 1993;181(1):31-37 (Pubitemid 23090147)
11. Soyka M, Albus M, Kathmann N, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci 1993;242(6):362-372 (Pubitemid 23225617)
12. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20(1-2):145-151 (Pubitemid 26387512)
13. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998;23(6):717-34 • Important review describing current models of comorbidity.
14. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6(3):132-91 • Gives evidence-based recommendations, based upon international consensus, for schizophrenia patients with comorbid substance abuse.
15. Soyka M, Kranzler HR, Berglund M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. World J Biol Psychiatry 2008;9(1):6-23 (Pubitemid 351250516)
16. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000;26(1):105-18 • Excellent review summarizing the available psychosocial interventions for dual-diagnosis patients and describing their effectiveness.
17. Wobrock T, Falkai P, Pajonk FG. Acute treatment of schizophrenia. Fortschr Neurol Psychiatr 2004;72(12):705-723 (Pubitemid 40006882)
18. Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotox Res 2007;11(1):33-40
19. Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder - reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1375-85 • Recent systematic review summarizing the available studies dealing with the pharmacotherapy of schizophrenia patients with comorbid substance abuse.
20. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192(4238):481-483
21. Fleischhacker WW. Second generation antipsychotics. Psychopharmacology (Berl) 2002;162(1):90-91 (Pubitemid 34639565)
22. Moller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 2000;1(2):75-91
23. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209- 1223 (Pubitemid 41345943)
24. Soyka M. Dual diagnosis in patients with schizophrenia. Issues in pharmacological treatment. CNS Drugs 1996;5:414-425
25. Wilkins JN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 1997;23(2):215-228 (Pubitemid 27224874)
26. Bowers MB Jr, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic drug use and neuroleptic response. Schizophr Bull 1990;16(1):81-85 (Pubitemid 20110377)
27. Scheller-Gilkey G, Woolwine BJ, Cooper I, et al. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse 2003;29(3):553-566 (Pubitemid 37093366)
28. Stuyt EB, Sajbel TA, Allen MH. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 2006;15(2):166-173
29. Petrakis IL, Leslie D, Finney JW, Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 2006;15(1):44-49 (Pubitemid 43207188)
30. Swanson J, Van Dorn RA, Swartz MS. Effectiveness of atypical antipsychotics for substance use in schizophrenia patients. Schizophr Res 2007;94(1-3):114-118 (Pubitemid 47031605)
31. Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006;32(4):637-643 (Pubitemid 44412851)
32. Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151(3):385-389 (Pubitemid 24081458)
33. Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55(Suppl B):114-116 (Pubitemid 24353032)
34. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26(2):441-449 (Pubitemid 30423220)
35. Kelly DL, Gale EA, Conley RR. Clozapine treatment in patients with prior substance abuse. Can J Psychiatry 2003;48(2):111-114 (Pubitemid 36402212)
36. Lee ML, Dickson RA, Campbell M, et al. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998;43(8):855-856 (Pubitemid 28518678)
37. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. Am J Psychiatry 1995;152(6):959
38. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000;20(1):94-98 (Pubitemid 30056360)
39. Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999;14(3):177-180
40. Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005;193(6):379-386 (Pubitemid 40800627)
41. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 2006;26(1):9-12 (Pubitemid 43167083)
42. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict 2007;16(4):260-268 (Pubitemid 47174581)
43. Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21(4):217-221 (Pubitemid 34041006)
44. Noordsy DL, O'keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999;60(Suppl 19):47-51; discussion 2-3 (Pubitemid 29446954)
45. Noordsy DL, O'Keefe C, Mueser KT, Xie H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 2001;52(4):501-507 (Pubitemid 32275312)
46. Gerra G, Di Petta G, D'Amore A, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol 2007;30(3):127-135 (Pubitemid 46871862)
47. Tsuang J, Marder SR, Han A, Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 2002;63(12):1180-1181 (Pubitemid 36084066)
48. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004;66(2-3):125-135 (Pubitemid 38041110)
49. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998;33(1-2):95-101 (Pubitemid 28439250)
50. Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 2003;23(4):384-388 (Pubitemid 36951181)
51. Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006;22(7):1277-1285 (Pubitemid 44085579)
52. Potvin S, Stip E, Roy JY. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry 2004;49(10):711 (Pubitemid 39524666)
53. Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 2003;33(1):85-89 (Pubitemid 36927701)
54. Berk M, Brook S, Nur F. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int J Psych Clin Pract 2000;4:139 (Pubitemid 30421599)
55. Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002;47(7):671-675 (Pubitemid 35192034)
56. Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994;151(5):780-781 (Pubitemid 24140576)
57. Gupta N, Basu D. Does risperidone reduce concomitant substance abuse in cases of schizophrenia? Can J Psychiatry 2001;46(9):862-863
58. Tsuang JW, Eckman T, Marder S, Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol 2002;22(6):629-630
59. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 2003;60(1):81-85 (Pubitemid 36015790)
60. Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(4):984-988 (Pubitemid 351609233)
61. Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005;25(4):363-366 (Pubitemid 41060257)
62. Desseilles M, Mathot F. Aripiprazole diminishes cannabis use in schizophrenia. J Neuropsychiatry Clin Neurosci 2008 (Winter);20(1):117-118 (Pubitemid 351295049)
63. Dervaux A, Cazali J. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. J Clin Psychopharmacol 2007;27(5):514-516 (Pubitemid 47415054)
64. Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res 2008;100(1-3):39-52
65. Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 1991;84(3):272-276
66. Levin FR, Evans SM, Coomaraswammy S, et al. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 1998;24(3):343-360 (Pubitemid 28402492)
67. Schilkrut R, Cabrera J, Morales E, Herrera L. Neuroleptics in the treatment of drug dependence in schizophrenics. A study with flupenthixol decanoate. Psychopharmacol 1998;96(Suppl):342
68. Soyka M, Sand P. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry 1995;28(2):64-65
69. Soyka M, Aichmuller C, v Bardeleben U, et al. Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur Addict Res 2003;9(2):65-72
70. Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51(8):531-9 • The design of the presented study picked up the earlier recommendations for depot antipsychotics in dual-diagnosis patients and compared a second generation with a first generation depot antipsychotic. The results of this a study of a large sample give evidence for the advantage of SGA.
71. Deutsche Gesellschaft fuer Psychiatrie, Psychotherapie und Nervenheilkunde, edition. Practice guidelines in psychiatry and psychotherapy. Book 1, Practice guideline. Schizophrenia. Guideline development group. In: Gaebel W, Falkai P, Winmann S, Wobrock T. Darmstadt: Steinkopff; 2006
72. Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4(5):231-44 • Description of the most cited historical model of the comorbidity of schizophrenia and substance abuse.
73. Siris SG, Mason SE, Bermanzohn PC, et al. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 1993;29(1):127-133 (Pubitemid 23204892)
74. Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992;28(3):309-314
75. Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol 2005;19(3):301-305
76. Gold MS, Donabedian RK, Dillard M Jr, et al. Antipsychotic effect of opiate agonists. Lancet 1977;2(8034):398-399 (Pubitemid 8164411)
77. Sernyak MJ, Glazer WM, Heninger GR, et al. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol 1998;18(3):248-251 (Pubitemid 28266892)
78. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172(3):291-297 (Pubitemid 38392322)
79. Maxwell S, Shinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis 2000;19(3):61-69 (Pubitemid 30844244)
80. Batki SL, Dimmock JA, Wade M, et al. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict 2007;16(4):253-259 (Pubitemid 47174579)
81. Kofoed L, Kania J, Walsh T, Atkinson RM. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 1986;143(7):867-872 (Pubitemid 16090392)
82. Mueser KT, Noordsy DL, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003;12(3):242-252 (Pubitemid 36950973)
83. Ewing JA, Mueller RA, Rouse BA, Silver D. Low levels of dopamine beta-hydroxylase and psychosis. Am J Psychiatry 1977;134(8):927-928 (Pubitemid 8151851)
84. Major LF, Lerner P, Ballenger JC, et al. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 1979;14(2):337-344
85. Drake RE. Management of substance use disorder in schizophrenia patients: current guidelines. CNS Spectr 2007;12(10 Suppl 17):27-32 •• Gives pragmatic recommendations, based on summarized clinical evidence, for the management of this patient group.
86. Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 1996;86(7):973-977 (Pubitemid 26242945)
87. Owen C, Rutherford V, Jones M, et al. Noncompliance in psychiatric aftercare. Community Ment Health J 1997;33(1):25-34 (Pubitemid 27108072)
88. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11(5):315-339 (Pubitemid 41540226)
89. Carey KB. Substance use reduction in the context of outpatient psychiatric treatment: a collaborative, motivational, harm reduction approach. Community Ment Health J 1996;32(3):291-306; discussion 7-10 (Pubitemid 126726317)
90. Gouzoulis-Mayfrank E. Dual diagnosis of psychosis and addiction. From principles to practice. Nervenarzt 2004;75(7):642-650
91. McHugo GJ, Drake RE, Burton HL, Ackerson TH. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis 1995;183(12):762-767
92. Roth RM, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep 2005;7(4):283-291
93. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991;148(2):224-230
94. Gawin FH. Neuroleptic reduction of cocaine-induced paranoia but not euphoria? Psychopharmacology (Berl) 1986;90(1):142-143
95. Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 1985;46(3):79-83 (Pubitemid 15147501)
96. Siris SG. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 1990;16(1):111-122 (Pubitemid 20110380)
97. Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry 2005;66(Suppl 6):21-26 (Pubitemid 41243258)
98. Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5(5):340-346 (Pubitemid 38899227)
99. Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 2003;18(3):121-32 • Authors provide theoretically based evidence, with regard to receptor profiles and reward circuitry, for advantages of SGAs in treating comorbid schizophrenia patients, and summarize the results of clinical studies.
100. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909 (Pubitemid 35231730)
101. Beresford TP, Arciniegas D, Clapp L, et al. Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications. Brain Inj 2005;19(4):309-313 (Pubitemid 40260103)
102. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50(2):71-83 •• Most cited reference explaining important aspects of the recent hypotheses concerning the neurobiological background of this comorbidity.
103. Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008;22(1):11-23
104. Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull 1984 (Summer);20(3):572-584 (Pubitemid 14090971)
105. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990;16(1-2):57-66 (Pubitemid 20107092)
106. Farren CK, Hameedi FA, Rosen MA, et al. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend 2000;59(2):153-163 (Pubitemid 30417420)